Xuanzhu Biotech-B (02575) saw its shares rise more than 10% during the morning trading session. At the time of writing, the stock was up 9.96%, trading at HK$34.46 with a turnover of HK$3.4138 million.
The surge follows an announcement from the company regarding a licensing and supply agreement. On April 9, 2026, the Group, acting as the licensor, entered into the agreement with Boston Oncology CGT Holding Co. Limited, the licensee, concerning piroplociclib (brand name: Xuan Yuening®) and diroac (brand name: Xuan Feining®).
Piroplociclib is a CDK2/4/6 inhibitor independently developed by the Group for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Diroac is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, also independently developed by the Group, intended for the treatment of ALK-positive advanced non-small cell lung cancer.
Under the terms of the licensing and supply agreement, the licensor has granted the licensee an exclusive license to develop, register, and commercialize both piroplociclib and diroac within the authorized territory, which encompasses 21 countries and regions in the Middle East and North Africa. The licensor will receive an upfront payment and is eligible for potential future regulatory and commercial milestone payments that could cumulatively exceed $100 million, in addition to fixed-percentage royalties based on the total sales within the licensed region. The licensor will also supply the products to the licensee at an agreed-upon price to support the commercial development activities for both drugs in the authorized territory.
Comments